350 related articles for article (PubMed ID: 18087054)
1. Brief communication: rituximab in HIV-associated multicentric Castleman disease.
Bower M; Powles T; Williams S; Davis TN; Atkins M; Montoto S; Orkin C; Webb A; Fisher M; Nelson M; Gazzard B; Stebbing J; Kelleher P
Ann Intern Med; 2007 Dec; 147(12):836-9. PubMed ID: 18087054
[TBL] [Abstract][Full Text] [Related]
2. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease.
Bower M; Veraitch O; Szydlo R; Charles P; Kelleher P; Gazzard B; Nelson M; Stebbing J
Blood; 2009 May; 113(19):4521-4. PubMed ID: 19224759
[TBL] [Abstract][Full Text] [Related]
3. Rituximab plus liposomal doxorubicin in HIV-infected patients with KSHV-associated multicentric Castleman disease.
Uldrick TS; Polizzotto MN; Aleman K; Wyvill KM; Marshall V; Whitby D; Wang V; Pittaluga S; O'Mahony D; Steinberg SM; Little RF; Yarchoan R
Blood; 2014 Dec; 124(24):3544-52. PubMed ID: 25331113
[TBL] [Abstract][Full Text] [Related]
4. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease.
Powles T; Stebbing J; Montoto S; Nelson M; Gazzard B; Orkin C; Webb A; Bower M
Blood; 2007 Dec; 110(12):4132-3. PubMed ID: 18024800
[No Abstract] [Full Text] [Related]
5. Coexistence of disseminated Kaposi sarcoma and multicentric Castleman disease in an HIV-infected patient under viral suppression.
Lin IF; Lin JN; Tsai TH; Hsu CT; Wu YY; Lai CH
Int J STD AIDS; 2021 Mar; 32(3):286-289. PubMed ID: 33555231
[TBL] [Abstract][Full Text] [Related]
6. Rituximab therapy for HIV-associated Castleman disease.
Marcelin AG; Aaron L; Mateus C; Gyan E; Gorin I; Viard JP; Calvez V; Dupin N
Blood; 2003 Oct; 102(8):2786-8. PubMed ID: 12842986
[TBL] [Abstract][Full Text] [Related]
7. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.
Nicoli P; Familiari U; Bosa M; Allice T; Mete F; Morotti A; Cilloni D; Saglio G; Guerrasio A
Int J Hematol; 2009 Oct; 90(3):392-396. PubMed ID: 19756920
[TBL] [Abstract][Full Text] [Related]
8. EBV+ HHV-8+ Multicentric Castleman Disease With Plasmablastic Aggregates in an HIV+ Man: An Evolving Clinicopathologic Entity.
Shivane A; Pearce A; Khatib N; Smith MEF
Int J Surg Pathol; 2018 Jun; 26(4):338-341. PubMed ID: 29198143
[TBL] [Abstract][Full Text] [Related]
9. HIV-associated multicentric Castleman disease.
Oksenhendler E
Curr Opin HIV AIDS; 2009 Jan; 4(1):16-21. PubMed ID: 19343828
[TBL] [Abstract][Full Text] [Related]
10. [PET-CT documented remission of multicentric Castleman disease after treatment with rituximab: case report and review].
Adam Z; Szturz P; Koukalová R; Řehák Z; Pour L; Krejčí M; Šmardová L; Eid M; Volfová P; Čermáková Z; Křen L; Sokol F; Hanke I; Michalková E; Král Z; Mayer J
Vnitr Lek; 2015 Mar; 61(3):251-9. PubMed ID: 25873122
[TBL] [Abstract][Full Text] [Related]
11. Complete remission and virologic response to combined chemoimmunotherapy (R-CVP) followed by rituximab maintenance in HIV-negative, HHV-8 positive patient with multicentric Castleman disease.
Fragasso A; Mannarella C; Ciancio A; Calvario A; Scarasciulli ML
Leuk Lymphoma; 2008 Nov; 49(11):2224-6. PubMed ID: 19021070
[No Abstract] [Full Text] [Related]
12. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy.
Corbellino M; Bestetti G; Scalamogna C; Calattini S; Galazzi M; Meroni L; Manganaro D; Fasan M; Moroni M; Galli M; Parravicini C
Blood; 2001 Dec; 98(12):3473-5. PubMed ID: 11719390
[TBL] [Abstract][Full Text] [Related]
13. How I treat HIV-associated multicentric Castleman disease.
Bower M
Blood; 2010 Nov; 116(22):4415-21. PubMed ID: 20688959
[TBL] [Abstract][Full Text] [Related]
14. Rituximab decreases the risk of lymphoma in patients with HIV-associated multicentric Castleman disease.
Gérard L; Michot JM; Burcheri S; Fieschi C; Longuet P; Delcey V; Meignin V; Agbalika F; Chevret S; Oksenhendler E; Galicier L
Blood; 2012 Mar; 119(10):2228-33. PubMed ID: 22223822
[TBL] [Abstract][Full Text] [Related]
15. Higher rate of progression in HIV- than in HIV+ patients after rituximab for HHV8+ multicentric Castleman disease.
Rasmussen C; Gérard L; Fadlallah J; Corvilain E; Galicier L; Meignin V; Oksenhendler E; Boutboul D
Blood Adv; 2023 Sep; 7(18):5663-5669. PubMed ID: 37288720
[TBL] [Abstract][Full Text] [Related]
16. Multicentric Castleman's disease in HIV infection: a systematic review of the literature.
Mylona EE; Baraboutis IG; Lekakis LJ; Georgiou O; Papastamopoulos V; Skoutelis A
AIDS Rev; 2008; 10(1):25-35. PubMed ID: 18385778
[TBL] [Abstract][Full Text] [Related]
17. Successful use of rituximab in glomerular basement membrane nephritis associated with HIV interstitial nephritis secondary to Castleman disease
.
Calabro N; Henriksen K; Lim SH; Kerns E
Clin Nephrol; 2018 Jun; 89(6):469-473. PubMed ID: 29424337
[TBL] [Abstract][Full Text] [Related]
18. Complete remission in a pancytopenic HIV negative, HHV-8 positive patient with multicentric Castleman's disease induced with anti-CD20.
Cervera Grau JM; Galiana Esquerdo G; Llorca Ferrándiz C; Briceño García H; Díaz Castellano M; Férriz Moreno P
Clin Transl Oncol; 2006 Jul; 8(7):540-1. PubMed ID: 16870545
[TBL] [Abstract][Full Text] [Related]
19. High-dose zidovudine plus valganciclovir for Kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.
Uldrick TS; Polizzotto MN; Aleman K; O'Mahony D; Wyvill KM; Wang V; Marshall V; Pittaluga S; Steinberg SM; Tosato G; Whitby D; Little RF; Yarchoan R
Blood; 2011 Jun; 117(26):6977-86. PubMed ID: 21487108
[TBL] [Abstract][Full Text] [Related]
20. Multicentric Castleman disease of hyaline vascular variant presenting with unusual systemic manifestations: a case report.
Basnayake BMDB; Wazil AWM; Kannangara T; Ratnatunga NVI; Hewamana S; Ameer AM
J Med Case Rep; 2017 May; 11(1):135. PubMed ID: 28501028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
